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During the past two decades, much interest has focused on the
pathogenic role of autoreactive T-cells recognizing myelin in
both multiple sclerosis and its animal model, experimental
autoimmune encephalomyelitis (EAE). The vast majority of
data support the hypothesis that EAE and, by analogy,
multiple sclerosis are diseases mediated by autoreactive Th1
T-cells, much as rheumatoid arthritis, autoimmune diabetes,
psoriasis or in¯ammatory bowel disease. Thus, much effort
has been put into developing multiple sclerosis therapies that
eliminate more or less speci®cally autoimmune T-cells or
shift the balance from the presumed pathogenic Th1 to the
presumed bene®cial Th2 phenotype of T-cells (Noseworthy
et al., 2000). The two currently approved disease modifying
treatments, IFN-b and glatiramer acetate (GA), are thought to
exert their bene®cial effect in multiple sclerosis at least in part
by this mechanism of action.
But clinical observations mainly related to the `clinical±
radiological paradoxon' indicate that suppression of a
deviated immune response may be an inappropriately
simplistic approach: (i) multiple sclerosis in¯ammatory
lesions, as depicted with high sensitivity by contrast enhanced
magnetic resonance imaging (MRI), did not predict later
changes in impairment or disability (Kappos et al., 1999);
(ii) in primary progressive and also late secondary progres-
sive multiple sclerosis, the disease courses most closely
associated with increasing disability, less in¯ammatory
changes are observed than in relapsing±remitting disease;
and (iii) currently available immunomodulatory and immuno-
suppressive treatments of multiple sclerosis have a much
more pronounced effect on in¯ammatory activity (as shown
by serial MRI) than on clinical disease.
Recently, an increasing body of experimental evidence
supports the hypothesis of a `dual role' of the immune system
in demyelinating disease, emphasizing potentially bene®cial
effects of in¯ammation. In a series of experiments it was
elegantly shown that in models of crush injury of the optic
nerve or contusion of the spinal cord in rats, activated T-cells
speci®c for CNS antigens, e.g. basic myelin protein, but not
against non-CNS antigens, protect the injured nervous system
tissue from secondary degeneration and promote repair
(Moalem et al., 1999, 2000; Cohen and Schwartz, 1999;
Yoles et al., 2001). This neuroprotective effect of auto-
immune T-cells is at least partly mediated by the release of
neurotrophic factors (Hohlfeld et al., 2000). Activated human
T-cells but also B-cells and macrophages produce neuro-
trophic factors (Kerschensteiner et al., 1999; Besser and
Wank, 1999). Extending the ®rst observations by
Kerschensteiner et al. (1999), detailed immunohistochemical
analysis (Stadelmann et al., 2002) has shown that brain-
derived neurotrophic factor (BDNF) and its receptor trkB are
present in multiple sclerosis lesions thus suggesting a role for
this neurotrophin in multiple sclerosis.
These ®ndings would have major therapeutic implications
if it were possible to obtain T-cells which react with CNS
antigens and exert such protective effects without the
destructive potential of CNS autoimmunity. GA should be a
logical candidate for the induction of such cells, as it is non-
pathogenic, capable of inducing a protective immune
response in EAE and partially bene®cial in relapsing±
remitting multiple sclerosis.
In this issue of Brain, Ziemssen et al. (2002) provide ®rm
evidence that indeed BDNF is secreted by GAA reactive
human T-cell lines in vitro. Interestingly, the four T-cell lines
described secreted roughly equal amounts of BDNF although
they were of stable Th0, Th1, Th2 or combined Th1/Th0
phenotypes, usually known for very diverging patterns of
cytokine secretion. They hypothesize that treatment with GA
in multiple sclerosis may not only exert an anti-in¯ammatory
effect by a shift from secretion of Th1 to Th2 cytokines (Duda
et al., 2000; Neuhaus et al., 2000) but in addition mediate
neuroprotection by the secretion of BDNF.
These data are in line with earlier results from Kipnis et al.
(2000) who found high secretion of BDNF and moderate
secretion of NT3, NT4/5 and NGF in both passively
transferred and actively induced GA reactive rat T-cells that
were capable of mediating neuroprotection in an optic nerve
crush injury model.
Although encouraging, these ®ndings provide only indirect
evidence of GA-speci®c T-cell induced neuroprotection in
the human disease multiple sclerosis. It is not clear if and in
what quantities GA-speci®c T-cells reach the CNS of
multiple sclerosis patients and ifÐonce thereÐthese cells
produce suf®cient quantities of BDNF and perhaps other
neurotrophins.
Recent neuroimaging ®ndings in patients treated with GA
seem to further support an anti-degenerative role of GA in
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multiple sclerosis: in addition to a signi®cant reduction of
in¯ammatory activity (which was less pronounced than in
similar studies with interferon-b) treatment with GA also
resulted in a decrease of the proportion of new lesions that
evolved into T1 hypointense lesions, a lesion type more
indicative of tissue destruction (Filippi et al., 2001). This
®nding as well as similar observations in the long term follow
up of the original patient cohort of the pivotal GA trial
(Wolinsky et al., 2001) are still controversial and derived
from secondary (post hoc) analysis and certainly need
con®rmation in prospective studies.
More research is needed to elucidate the roles of immune
cells in neuroprotection and repair mechanisms in the CNS, if
we ultimately want to explore the Janus shape of autoimmune
myelin reactive T-cells in CNS diseases for the development
of future therapeutics.
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